Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Incyte Corporation

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY) and Dyne Therapeutics (DYN). Incyte ...

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Dyne Therapeutics (DYN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on PROCEPT BioRobotics (PRCT) and Incyte (INCY). PROCEPT BioRobotics...

Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Incyte (INCY)

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Incyte today and set a price target of $123.00. Willey covers the Healthcare sect...

Stifel Nicolaus Keeps Their Buy Rating on Incyte (INCY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Krystal Biotech (KRYS), Incyte (INCY) and Acurx Phar...

Analysts Are Bullish on These Healthcare Stocks: Krystal Biotech (KRYS), Incyte (INCY)

Guggenheim analyst maintained a Buy rating on Incyte today and set a price target of $130.00. In addition to Guggenheim, Incyte also received a Buy...

Guggenheim Sticks to Its Buy Rating for Incyte (INCY)

In a report released on April 30, from Argus Research maintained a Buy rating on Incyte, with a price target of $115.00. The company’s shares close...

Argus Research Keeps Their Buy Rating on Incyte (INCY)

BMO Capital analyst Evan Seigerman maintained a Sell rating on Incyte today and set a price target of $75.00. According to TipRanks, Seigerman is a...

BMO Capital Sticks to Its Sell Rating for Incyte (INCY)

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Incyte, with a price target of $135.00. According to Ti...

H.C. Wainwright Sticks to Its Buy Rating for Incyte (INCY)

In a report released today, Evan Seigerman from BMO Capital maintained a Sell rating on Incyte, with a price target of $75.00. Seigerman covers the...

BMO Capital Remains a Sell on Incyte (INCY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Axsome Therapeutics (AXSM), Intellia Therapeutics (NTLA) and Incy...

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Intellia Therapeutics (NTLA) and Incyte (INCY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Incyte (INCY) and Zymeworks (ZYME) with bullish sent...

Market Cap	$17.10B	P/E Ratio	14.41
52W High	$112.29	52W Low	$63.93
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	62.7%	52W Position	68.6%
Overall Score	69	Value Score	80
Quality Score	68	Technical Score	60

EPS Current Est	$6.74	EPS Next Est	$7.95
EPS Growth Est	+18.0%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INCY	$97.10	-0.06%	1.18M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INCY	$97.10	-0.1%	1.18M
3
4
5
6

INCY

INCY

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Incyte Corporation Data in Excel

Get Incyte Corporation Data in Excel